HELP Stock Analysis: Cybin Common Stock | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 410m USD | 12M Return: -23.4% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 4.53M
Warnings
Tailwinds
No distinct edge detected
Seasonality 6.8 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Cybin Inc. (HELP) is a Canadian clinical-stage biopharmaceutical company focused on developing psychedelic-based therapeutics for neuropsychiatric conditions. Its core pipeline utilizes deuterated molecules, which are chemically modified to potentially improve the metabolic profile and duration of action compared to traditional psychedelic compounds.
The company’s lead candidate, CYB003, is a deuterated psilocybin analog currently entering Phase 3 clinical trials for the treatment of Major Depressive Disorder (MDD). Additionally, Cybin is advancing CYB004, a deuterated DMT molecule in Phase 2 trials for Generalized Anxiety Disorder, alongside several preclinical programs targeting central nervous system disorders.
The psychedelic medicine sector operates under a high-risk, high-reward model characterized by long regulatory approval timelines and significant capital requirements for late-stage clinical trials. For a deeper look at the underlying fundamentals, you may find ValueRay to be a useful resource for further research. To support its pivotal Phase 3 program, Cybin maintains a strategic partnership with Segal Trials to facilitate multinational clinical data collection.
- CYB003 Phase 3 clinical trial results for Major Depressive Disorder
- FDA Breakthrough Therapy Designation accelerates regulatory approval timeline
- Cash runway and future equity raises impact capital structure
- Competitive landscape for psychedelic-based therapeutics and deuterated psilocybin analogs
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.56 > 0.02 and ΔFCF/TA -2.42 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.55 > 3% & CFO -138.5m > Net Income -160.6m |
| Net Debt/EBITDA: error (cannot be calculated) |
| Current Ratio: 9.52 > 1.5 & < 3 |
| Outstanding Shares: last quarter (50.3m) vs 12m ago 132.7% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.0%; Δ 0.0% > 0%) |
| Interest Coverage Ratio: -37.92 > 6 (EBIT TTM -153.3m / Interest Expense TTM 4.04m) |
| A: 0.66 (Total Current Assets 185.1m - Total Current Liabilities 19.4m) / Total Assets 252.0m |
| B: -1.55 (Retained Earnings -390.8m / Total Assets 252.0m) |
| C: -0.71 (EBIT TTM -153.3m / Avg Total Assets 215.9m) |
| D: 11.96 (Book Value of Equity 232.6m / Total Liabilities 19.4m) |
| Altman-Z'' = 7.05 = AAA |
As of July 08, 2026, the stock is trading at USD 6.03 with a total of 867,013 shares traded. Over the past week, the price has changed by -12.35%, over one month by +50.37%, over three months by +14.86% and over the past year by -23.38%.
Current recommended Stop Loss: 5.50 (which is 8.8% or 1.3 ATR below the current price).
Cybin Common Stock has no consensus analysts rating.
Market Cap CAD = 581.7m (409.8m USD * 1.4196 USD.CAD)
P/S = 16436.3617
P/B = 1.7679
Revenue TTM = 0.0 CAD
EBIT TTM = -153.3m CAD
EBITDA TTM = -153.2m CAD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 423.9m CAD (581.7m + (null Debt) - CCE 157.8m)
Interest Coverage Ratio = -37.92 (Ebit TTM -153.3m / Interest Expense TTM 4.04m)
EV/FCF = -3.03x (Enterprise Value 423.9m / FCF TTM -140.0m)
FCF Yield = -33.02% (FCF TTM -140.0m / Enterprise Value 423.9m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 154k) / Revenue TTM)
Tobins Q-Ratio = 1.68 (Enterprise Value 423.9m / Total Assets 252.0m)
Interest Expense / Debt = unknown (Interest Expense 4.04m / Debt none)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -121.1m (EBIT -153.3m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 9.52 (Total Current Assets 185.1m / Total Current Liabilities 19.4m)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA -153.2m)
Debt / FCF = unknown (Net Debt none / FCF TTM -140.0m)
Total Stockholder Equity = 202.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -74.38% (Net Income -160.6m / Total Assets 252.0m)
RoE = -79.17% (Net Income TTM -160.6m / Total Stockholder Equity 202.9m)
RoCE = -65.92% (EBIT -153.3m / Capital Employed (Total Assets 252.0m - Current Liab 19.4m))
RoIC = -52.07% (negative operating profit) (NOPAT -121.1m / Invested Capital 232.6m)
WACC = 11.67% (E(581.7m)/V(581.7m) * Re(11.67%) + (debt-free company))
Discount Rate = 11.67% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 90.80 | Cagr: 117.2%
[DCF] Fair Price = unknown (Cash Flow -140.0m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.09 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: N/A | # QB: 0
EPS current Quarter (2026-06-30): EPS=-1.23 | Chg30d=-7.24% | Revisions=-17% | Analysts=4
EPS next Quarter (2026-09-30): EPS=-1.11 | Chg30d=-2.35% | Revisions=-17% | Analysts=4
EPS current Year (2027-03-31): EPS=-4.59 | Chg30d=-4.34% | Revisions=-17% | GrowthEPS=+22.4% | GrowthRev=+0.0%
EPS next Year (2028-03-31): EPS=-3.96 | Chg30d=-1.58% | Revisions=+0% | GrowthEPS=+13.6% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: -21% (up=4, down=7)